1. Margriet V.D.Z. Park, PhD
Expert in innovative strategies and methods in the area of human health risk
assessment of nanotechnology and medical technology.
Vital Statistics
Name: Margriet van der Zee Park
Address: Utenhamstraat 2, 3451 BR
Vleuten, the
Netherlands
Telephone: +31 6 27576936
Email: margriet.park@gmail.com
Date of Birth: February 19, 1976
Place of Birth: Leeuwarden, the Netherlands
Nationality: Dutch
Key words
Critical analytical thinker with eye for detail, enthusiastic, fast learner, entrepreneurial,
innovative, determined.
Work experience
2011 – present
National Institute for Public Health and the Environment (RIVM)
Senior scientist nanotechnology and medical technology
• Acquisition of (inter)national research projects
• Coordination and management of (inter)national research projects
• Strategy and method development for risk assessment
• Supervision of PhD students
• Participation in expert committees
• Contribution to development of innovative software
• Monitoring scientific and regulatory developments
2007 – 2011
National Institute for Public Health and the Environment (RIVM)
Maastricht University, Department of Toxicogenomics
PhD thesis: Nanotoxicology – an in vitro approach
• Evaluation of use of in vitro assays for risk assessment of nanomaterials
• Investigation of possibilities to extrapolate safety data between nanomaterials
• Development of approach to determine adequate dose metrics for
nanomaterials
January 9, 2017 Margriet V.D.Z. Park CV
page 1

2. 2004-2007
National Institute for Public Health and the Environment (RIVM)
Scientist chemical risk assessment
• Development of chemical exposure assessment tool ConsExpo
• Exposure and risk assessment of chemicals in consumer products
• Chemical risk assessment of worker’s exposure
2002-2004
Lipid Nutrition Loders Croklaan B.V
Toxicologist
• Toxicological screening of potential food supplement ingredients
• Preparation of regulatory documents for registration of food supplement
ingredients
2001-2002
Michigan State University Aquatic Toxicology Laboratory
Research assistant
• Development of study proposal of the herbicide atrazine on the reproductive
success of amphibians.
• Participation in an Ecological Risk Assessments of the Kalamazoo River and
Tittabawassee River, Michigan Superfund Site
1995-1996
Development Aid from People to People (DAPP), Kukwanisa, Zimbabwe
Volunteer developmental aid
• Enrolling families in education programme on personal hygiene and lifesaving
skills
Academics
2007-2012 PhD; Nanotoxicology
Maastricht University
Department of Toxicogenomics
1996-2001 MSc; Biology
Wageningen University
1992-1994 International Baccalaureate
United World College of the Atlantic, Wales, UK
January 9, 2017 Margriet V.D.Z. Park CV
page 2

3. Training, registration and skills
2015 Entrepreneurship in practice
TIAS School for Business and Society
2015 Adverse Outcome Pathways
RIVM
2012 Mediatraining
Marcel Hamming MH Media BV
2010 Personal Efficiency Program
VWS
2010 Drug Development Cycle
TI Pharma
2009 Fysische Chemie 3 – Colloïden
Universiteit Utrecht
2008 S-Plus
RIVM
2008 Biostatistiek
Universiteit Utrecht
2006 Projectmatig werken
RIVM
2006 Immunotoxicologie
Universiteit Utrecht
2005 Principles of Toxicological Pathology
University of Surrey, UK
2004 Principles of Experimental Toxicology
and Risk Assessment
University of Surrey, UK
2004 Carcinogenicity and Mutagenicity
University of Surrey, UK
2002 Good Clinical Practice
DOCS, Zeist
2002 Biological Safety Training
Michigan State University, USA
2001 Radiation Safety Initial Training
Michigan State University, USA
2001 Chemical Hygiene and Laboratory
Safety Training
Michigan State University, USA
2000 Proefdierkunde
Universiteit Utrecht
• EUROTOX registered toxicologist since October 2006
• Excellent Dutch and English written and verbal communication
January 9, 2017 Margriet V.D.Z. Park CV
page 3

4. List of Publications
Giannakou C, Geertsma RE, de Jong WH, van Loveren H, Vandebriel R, Park MVDZ. 2016.
Immunotoxicity Testing of Nanomedicinal Products: Possible Pitfalls in Endotoxin
Determination. Current Bionanotechnology, in press.
Giannakou C, Park MVDZ, de Jong WH, van Loveren H, Vandebriel R, Geertsma RE. 2016.
A comparison of immunotoxic effects of nanomedicinal products with regulatory
immunotoxicity testing requirements. Int J Nanomed, 11, 293-2952.
Braakhuis HM, Giannakou C., Peijnenburg WJ, Vermeulen J., van Loveren H, Park MVDZ. 2016.
Simple in vitro models can predict pulmonary toxicity of silver nanoparticles. Nanotoxicology 10(6),
770-9.
Peijnenburg WJGM, Delmaar CJ, Oomen AG, Chen J, de Jong WH, Sips AJAM, Wang Z,
Park MVDZ. 2015. A practical approach to determine dose metrics for nanomaterials.
Environmental Toxicology and Chemistry 01/2015; 34(5). DOI:10.1002/etc.2878
Hougaard KS, Campagnolo L, Chavatte-Palmer P, Tarrade A, Rousseau-Ralliard D,
Valentino S, Park MVDZ, de Jong WH, Wolterink G, Piersma AH, Ross BL, Hutchison GR,
Hansen JS, Vogel U, Jackson P, Slama R, Pietroiusti A, Cassee FR. 2015. A perspective on
the developmental toxicity of inhaled nanoparticles Reproductive Toxicology 06/2015; 11.
DOI:10.1016/j.reprotox.2015.05.015
Braakhuis HM, Cassee FR, Fokkens PHB, de la Fonteyne LJJ, Oomen AG, Krystek WH, van
Loveren H, Park MVDZ. 2015. Identification of the appropriate dose metric for pulmonary
inflammation of silver nanoparticles in an inhalation toxicity study. Nanotoxicology
02/2015; DOI:10.3109/17435390.2015.1012184
Braakhuis HM, Kloet SK, Keziç S, Kuper F, Park MVDZ, Bellmann S, van der Zande M, le
Gac S, Krystek P, Peters RJB, Rietjens IMCM, Bouwmeester H. 2015. Progress and future
of in vitro models to study translocation of nanoparticles. Archives of Toxicology
05/2015; DOI:10.1007/s00204-015-1518-5
Noorlander CW, Kooi MW, Oomen AG, Park MVDZ, Vandebriel RJ, Geertsma RE. 2015.
Horizon scan of nanomedicinal products. Nanomedicine 02/2015; 10(10):1-10.
DOI:10.2217/nnm.15.21
Park MVDZ, Noorlander CW, Oomen AG, Vandebriel RJ, Geertsma RE. 2014.
Nanotechnologie – kansen en risico’s van nanogeneesmiddelen. MFM - Tijdschrift over
praktijkgerichte farmacotherapie 3-2014.
Braakhuis HM, Gosens I, Krystek P, Boere JAF, Cassee FR, Fokkens PHB, Post JA, van
Loveren H, Park MVDZ. Particle size dependent deposition and pulmonary inflammation
after short-term inhalation of silver nanoparticles. 2014. Particle and Fibre Toxicology
09/2014; 11(1):49. DOI:10.1186/s12989-014-0049-1
Braakhuis HM, Park MVDZ, Gosens I, de Jong WH, Cassee FR. 2014. Physicochemical
characteristics of nanomaterials that affect pulmonary inflammation. Particle and Fibre
Toxicology 04/2014; 11(1):18
January 9, 2017 Margriet V.D.Z. Park CV
page 4

5. Herberts CA, Park MVDZ, Pot JWGA, de Vries CGJCA. 2014. Results from a horizon scan
on risks associated with transplantation of human organs, tissues and cells: from donor
to patient. Cell and Tissue Banking 05/2014; DOI:10.1007/s10561-014-9450-0
Ahluwalia Arti, Ahtiainen Jukka, Aitken Robert, Alenius Harri, Christof Asbach, Toby
Athersuch, Ulrika Backman, Enrico Bergamaschi, Markus Berges, Jos Bessems, [...], Kees
van Gestel, Rob Vandebriel, Esa Vanhala, Socorro Vázquez-Campos, Minnamari Vippola,
Ulla Vogel, Frank von der Kammer, Peter Wick, Margrethe Winther-Nielsen, Volkan Özgüz
et al. 2013. Nanosafety in Europe 2015-2025: Towards Safe and Sustainable
Nanomaterials and Nanotechnology Innovations 2013. Finnish Institute of Occupational
Health, Helsinki., ISBN: 978-952-261-310-3; 978-952-261-311-0
Krystek P, Park MVDZ, Braakhuis H, Jong WH. 2013. Applications of Inductively Coupled
Plasma-Mass Spectrometry in Biodistribution Studies of (Engineered) Nanoparticles.
Encyclopedia of Analytical Chemistry: Wiley & Sons, Ltd.
De Jong WH, van der Ven LT, Sleijffers A, Park MVDZ, Jansen EH, van Loveren H. 2013
Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated
dose toxicity study in rats. Biomaterials 34(33):8333-43.
Park MVDZ, Lynch I, Ramírez-García S, Dawson KA, de la Fonteyne L, Gremmer E, Briedé
JJ, Slob W, Elsaesser A, Howard CV, Van Loveren H, De Jong W. 2011. In vitro evaluation
of cytotoxic and inflammation properties of silica nanoparticles of different sizes in
murine RAW 264.7 macrophages. J Nanopart Res 13(12):6775-6787.
Park MVDZ, Neigh AM, Vermeulen JP, de la Fonteyne LJ, Verharen HW, Briede JJ, van
Loveren H, de Jong WH. 2011. The effect of particle size on the cytotoxicity,
inflammation, developmental toxicity and genotoxicity of silver nanoparticles.
Biomaterials 32(36):9810-7.
Colognato R, Park MVDZ, Wick P, De Jong WH. 2012. Interactions with the Human Body.
In: Adverse Effects of Engineered Nanomaterials: Exposure, Toxicology and Impact on
Human Health. Fadeel B, Pietroiusti A, Shvedova AA, editors. Amsterdam: Elsevier.
Park MVDZ, Verharen HW, Zwart E, Hernandez L, van Benthem J, Elsaesser A, Barnes C,
McKerr G, Salvati A, Lynch I, Dawson KA, de Jong WH. 2011. Genotoxicity evaluation of
silica nanoparticles of different sizes using the micronucleus and the plasmid lacZ gene
mutation assay. Nanotoxicology 5:168-81.
Park MVDZ, Annema W, Salvati A, Lesniak A, Elsaesser A, Barnes C, McKerr G, Howard
CV, Lynch I, Dawson KA et al. 2009. In vitro developmental toxicity test detects
inhibition of stem cell differentiation by silica nanoparticles. Toxicol Appl Pharmacol
240:108-116.
Park MVDZ, Lankveld DPK, van Loveren H, de Jong W. 2009. The status of in vitro
toxicity studies in risk assessment of nanomaterials. Nanomedicine 4(6):669-685.
January 9, 2017 Margriet V.D.Z. Park CV
page 5

6. O' Shea, M., Van der Zee, M. and Mohede, ICM. Conjugated Linoleic Acids - Sources and
Clinical Studies (2005) IN: Healthful Lipids. American Oil Chemists' Society (AOCS) p249-
272.
January 9, 2017 Margriet V.D.Z. Park CV
page 6

7. O' Shea, M., Van der Zee, M. and Mohede, ICM. Conjugated Linoleic Acids - Sources and
Clinical Studies (2005) IN: Healthful Lipids. American Oil Chemists' Society (AOCS) p249-
272.
January 9, 2017 Margriet V.D.Z. Park CV
page 6